Please ensure Javascript is enabled for purposes of website accessibility

Why Sarepta Therapeutics, Allegheny Technologies, and Capital Product Partners Slumped This Morning

By Dan Caplinger - Apr 26, 2016 at 11:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Earnings season continued to have a big impact on the market on Tuesday. Find out why these stocks fell.


Image: Allegheny Technologies.

Tuesday began on a quiet note for the stock market, with major market benchmarks inching higher in the first hour of trading. Many investors are still in wait-and-see mode with the Federal Reserve's monetary policy decision-makers meeting today and Wednesday, but earnings season has continued to have a major impact on market sentiment. Despite a lack of overall volatility in the broader market, some stocks fell sharply, and Sarepta Therapeutics (SRPT -3.97%), Allegheny Technologies (ATI 0.30%), and Capital Product Partners (CPLP -4.18%) were among the worst performers in early trading.

Sarepta Therapeutics plunged more than 35% in the first hour of trading after an FDA advisory panel voted late yesterday not to recommend approval of the company's eteplirsen treatment for muscular dystrophy. As Sarepta described it in a press release, the FDA panel voted against the proposition that there was substantial evidence from adequate and well-controlled studies that show production of dystrophin in clinically beneficial levels, and it also rejected a finding of effectiveness for the treatment of Duchenne muscular dystrophy. Several analysts downgraded the stock after the findings were announced, and Sarepta's hopes now hinge on whether the full FDA will decide to approve the drug at its anticipated meeting in late May despite the advisory panel's votes. If not, then Sarepta will likely have to conduct more studies in hopes of gaining approval further along in the clinical process.

Allegheny Technologies fell 6% after the company released its first-quarter earnings. The specialty materials company said that sales climbed 3% from year-ago levels, with rising sales of its high-performance materials and components segment offsetting a decline in sales of flat-rolled products. However, the company wasn't able to turn those sales into profits, and even after adjusting for certain restructuring and other one-time costs, Allegheny posted adjusted losses of $63 million, or $0.58 per share. Although Allegheny is benefiting from particular strength in the aerospace industry because of its contribution toward production of commercial aircraft and jet engines, the company is still seeing what it called "a period of continuing low raw material prices and uncertain end market demand" for its rolled products business. Until these commodity markets start to recover, Allegheny could remain under pressure.

Finally, Capital Product Partners dropped 28%. The shipping-company limited partnership slashed its distribution by more than two-thirds in the wake of its first-quarter financial results, which included roughly flat net income from year-ago levels. Capital Product Partners said that it had created a capital reserve in order to address increases in the cost of its obtaining capital, and the decline in the price of its common units necessitated the decision to conserve capital by restraining distributions to investors. In addition, with one of its major customers having to restructure its operations, Capital Product Partners is going through considerable uncertainty. By cutting the distribution, the company will be able to deal with debt coming due and improve its balance sheet, but it's bad news for unitholders who grew accustomed to impressive distribution yields.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
SRPT
$68.47 (-3.97%) $-2.83
Allegheny Technologies Incorporated Stock Quote
Allegheny Technologies Incorporated
ATI
$27.04 (0.30%) $0.08
Capital Product Partners L.P. Stock Quote
Capital Product Partners L.P.
CPLP
$15.13 (-4.18%) $0.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
349%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.